Clinical trial · Observational
Molecular-Genetic Correlates of Fatigue in Cancer Patients Receiving Localized External Beam Radiation Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Background: * Researchers have studied the causes of fatigue during treatments for various diseases, but these results have not been conclusive. * More information on the physical changes that affect the body during treatment may help identify biological or chemical factors that contribute to patient fatigue, which may allow physicians to identify individuals who may be more at risk of feeling fatigue before, during, and after treatment for diseases such as cancer. Objectives: * To identify factors contributing to fatigue in men who are undergoing radiation treatment for prostate cancer. Eligibility: * Men 18 years of age and older who are scheduled to receive localized radiation treatment for prostate cancer. Design: * Six outpatient visits to the NIH Clinical Center, approximately on the same day and same time of day: * First visit before beginning radiation treatment. * Once a week for the first 2 weeks of the treatment, once at the midpoint of treatment, once at the end of treatment. * Final visit 4 weeks after completion of radiation treatment. * Initial visit will involve a physical examination and questions about medical history. * Evaluations during the treatment period: * Blood draws to identify cells and chemicals associated with inflammation and fatigue. * Questions about physical activity, fatigue, depression, and quality of life.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Fatigue | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Patients
- description
- Prostate cancer patients
Primary outcomes (1)
- measure
- Change in Fatigue Score measured by PROMIS-Fatigue scale
- timeFrame
- Ongoing
Secondary outcomes (1)
- measure
- Change in gene expression, cytokine profile, skeletal muscle strength, cognitive function
- timeFrame
- Ongoing
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
* INCLUSION CRITERIA: To be included, patients must meet all of the following criteria: * Clinically localized prostate cancer with or without prior prostatectomy; * Scheduled to receive EBRT either by 3D conformal or IMRT techniques that is not anticipated to change during the course of the study, with or without ADT; * No known medical history of tuberculosis (TB); * Able to provide written informed consent by passing at least 80% of the consent quiz; * Greater than or equal to18 years of age; The control group must meet all the inclusion criteria mentioned above except for number 2. The control group must not be receiving any form of treatment for their prostate cancer to include hormone, immune, radiation, or chemotherapy. EXCLUSION CRITERIA: All participants with any one of the following criteria will be excluded: Progressive or unstable disease of any body system causing clinically significant fatigue, including cardiovascular, pulmonary, gastrointestinal, central nervous system, psychiatric, endocrine, hematologic, renal, or immunologic disorders, and including patients with any of the following broad disease categories: * Systemic infections (e.g., human immunodeficiency virus (HIV), active hepatitis); * Documented history of major depression, bipolar disease, psychosis, or alcohol dependence/abuse within the past 5 years; * Uncorrected hypothyroidism and anemia; * Chronic inflammatory disease that may be anticipated to alter the proinflammatory cytokine profile (i.e. rheumatoid arthritis, systemic lupus erythematosus, and cirrhosis). Patients taking tranquilizers, steroids, and nonsteroidal anti-inflammatory agents because these medications are known to affect cytokine production; Patients who have second malignancies or those receiving chemotherapy with their EBRT. In addition to the above criteria, participants with the following conditions will be excluded from participating in the exercise interventions: 1. Significant Restrictive or Obstructive Lung Disease 2. Ischemic heart disease 3. Left ventricular dysfunction 4. Acute corpulmonale 5. Cardiomyopathy (dilated, hypertrophic, or non-idiopathic) 6. Significant renal or hepatic dysfunction 7. Disabling stroke 8. Uncontrolled diabetes mellitus with a history of diabetic ketoacidosis 9. Mitochondrial disease Participants unable to pass the English comprehension test will be unable to take the Computer Assessment of Mild Cognitive Impairement (CAMCT) test but will be asked to complete the other outcome measures of the study. Self report of color-blindness, verified by taking the Ishihara card test and scoring greater than 14 (more or less than 10 minutes), will exclude a participant from taking the STROOP test, but will be asked to complete the other outcome measures of the study. This card test will be administered only if the patient states they are color blind. \- Individuals capable of becoming pregnant.
References
Publications (0)
Data not yet available